NuScale Power · NYSE · Pre-commercial regulatory-moat option on nuclear renaissance
Only NRC-approved U.S. SMR developer — regulatory moat is real, but zero binding contracts in three years and accelerating cash burn make this a high-variance binary bet on first commercialisation.
What it does: NuScale designs small modular nuclear reactors and licenses that technology to utilities and governments — think a factory-built nuclear plant you assemble on site rather than constructing from scratch.
Making or burning money? Burning heavily. Revenue was $31.5M in FY2025 against a -$689.6M operating loss. The company has never built a commercial reactor and true reactor revenue is a 2030+ event at best.
Why it's interesting: NuScale holds the only U.S. NRC-approved SMR designs — a genuine regulatory moat built over years and hundreds of millions of dollars. Data center power demand is structurally surging and nuclear is the only firm, 24/7, low-carbon answer. If commercialization materialises, the upside is very large.
The one big risk: NuScale's only ever firm commercial contract (UAMPS) cancelled in 2023 after estimated costs nearly doubled. Nearly three years later, there is still not a single binding commercial order. The company survives on serial equity dilution — with 662M shares authorized against a materially expanded float — and the cash runway is thin relative to burn.
What you'd be betting on: That the RoPower Romania Final Investment Decision or a TVA/ENTRA1 binding power purchase agreement closes in the next 12 months, turning three years of "advanced discussions" into a first signed contract before dilution further impairs the equity.
The structural demand thesis for SMRs is real and accelerating. U.S. data center electricity demand is projected to grow from ~17 GW (2022) to ~35 GW by 2030 (IEA), and global data centers may consume ~945 TWh/year by 2030 — roughly 3x current levels. Hyperscalers (Microsoft, Google, Meta, AWS) have collectively announced plans to finance more than 20 GW of advanced nuclear/SMR capacity. Nuclear is uniquely suited to this demand because it is firm, 24/7, dispatchable, and low-carbon — qualities wind/solar cannot match without massive storage costs. The U.S. policy environment is sharply supportive: the Energy Secretary told Congress in April 2026 that the first 5-10 new reactors will "almost certainly" receive DOE loan support. On a 10-year horizon, the structural thesis is genuine: IEA projects SMRs enter the baseload mix post-2030, and over 144 reactors across multiple vendors are in various licensing or deployment pipelines globally. NuScale's specific positioning within this thesis depends on converting its regulatory head-start into firm orders before better-capitalised or hyperscaler-backed rivals eat the addressable market.
Deeply pre-commercial and diluting continuously, but if the Romania FID or TVA/ENTRA1 binding PPA closes — making NuScale the only company with an NRC-approved design, modules in production, and a signed commercial contract — the stock could re-rate several-fold from current levels toward the $25-45 analyst range.
Multi-year SEC XBRL financials (revenue & net income).
Fair-value method: Scenario-weighted range. Lower bound ($7, aligned with Citi May 2026 target): no binding contract by end-2026, continued ATM dilution, de-rating toward ~$3.5B market cap or ~4x current annual liquidity. Upper bound ($22): Romania FID signed plus DOE loan conditional commitment in 2026, re-rating toward 10x P/S on a hypothetical $150-200M forward licensing/engineering revenue run-rate. The Barclays $45 target is excluded as it requires the full TVA/ENTRA1 6 GW program on schedule with no current contractual basis — not supportable on a 12-month horizon. Current price $13.95 sits near the midpoint of this range.
A modeled estimate, not a price target, not advice.
NuScale is the only U.S. company with full NRC SMR design approvals (50 MWe Design Certification 2022; 77 MWe Standard Design Approval May 2025) in a market where regulatory clearance is a multi-year, multi-hundred-million-dollar barrier. However, being first to NRC approval has not translated into first to revenue: the company has zero binding commercial contracts as of June 2026, its only firm order (UAMPS) cancelled in 2023, and better-capitalised or hyperscaler-backed rivals (Oklo, Kairos, X-energy) are closing the regulatory gap. Oklo at $11.6B market cap now exceeds NuScale's $4.5B despite holding no full NRC design certification — signalling that the market is pricing competitor pipelines and hyperscaler relationships above pure regulatory head-start. NuScale is structurally well-positioned on paper; operationally it is a pre-commercial option on the nuclear renaissance, not a cash-flowing business.
| | | |---|---| | Ticker | SMR (NYSE) | | Price | $13.95 | | Market cap | $4.54B | | FY2025 revenue | $31.5M | | FY2025 operating loss | -$689.6M | | FY2025 operating cash flow | -$459.6M | | FY2025 year-end cash | $836M | | Rating | 3.5 / 10 — Weak | | Risk badge | YELLOW | | Gate flags | None confirmed |
---
NuScale Power designs small modular nuclear reactors and licenses that technology to utilities, governments, and industrial customers. Its core product is the VOYGR plant — a scalable configuration of factory-built 77 MWe reactor modules (uprated from the original 50 MWe design) that can be assembled on-site to deliver between 77 MWe and 924 MWe (12-module VOYGR-12). NuScale does not build reactors itself; it licenses its certified design and earns engineering and licensing fees ahead of plant construction. The company holds two U.S. NRC approvals: a 50 MWe Design Certification (2022) and a 77 MWe Standard Design Approval (May 2025) — the only full NRC SMR design approvals held by any company. It has an exclusive global commercialisation partner, ENTRA1, and a manufacturing relationship with Doosan (South Korea), which reportedly has 12 VOYGR modules in production.
---
NuScale's commercialisation strategy centres on three parallel tracks: (1) closing the RoPower Romania Final Investment Decision (FID) for a 6-module, 462 MWe plant — the project has been in Front-End Engineering and Design (FEED) studies since 2021 and the FID has slipped from Q2 2026 to mid-late 2026 or early 2027; (2) advancing the TVA/ENTRA1 6 GW collaborative agreement (September 2025) into binding power purchase agreements (PPAs) for up to six plants across TVA's seven-state region, targeting first power ~2030; and (3) securing a DOE loan guarantee conditional commitment to remove the financing overhang that prevents customers from signing. Management has also stated that a first operating plant by 2030 is achievable "if we get closure on a deal here soon." The company's financial plan through to first commercial revenue is explicitly dependent on ongoing ATM equity issuances and potential additional offerings — the 662M authorized share ceiling (vs. a materially expanded float post-offerings and ATM activity) reflects this.
---
Revenue (FY, USD):
| Year | Revenue | |---|---| | 2020 | $0.6M | | 2021 | $2.9M | | 2022 | $11.8M | | 2023 | $22.8M | | 2024 | $37.0M | | 2025 | $31.5M |
Revenue grew from $0.6M (2020) to $37.0M (2024) driven by engineering and technology licensing fees, then declined to $31.5M in FY2025 (-14.9% YoY). Q1 2026 revenue was $0.6M (per press release, not XBRL-confirmed) — a sharp quarter decline attributed to the non-recurrence of one-time Romania technology license recognition that inflated Q1 2025. Note: FY2024 revenue of $37.0M was +62.4% above FY2023's $22.8M, not a decline — the improvement was partly driven by lumpy license recognition.
Operating income (FY, USD):
| Year | Operating income | |---|---| | 2020 | -$158.8M | | 2021 | -$174.3M | | 2022 | -$230.0M | | 2023 | -$275.6M | | 2024 | -$138.7M | | 2025 | -$689.6M |
FY2024 showed a genuine improvement (operating loss narrowed from -$275.6M to -$138.7M). FY2025 reversed that sharply, with the operating loss nearly 5x the prior year (-$689.6M). The FY2025 figure includes restructuring charges and non-cash items, but the underlying cash burn trajectory is consistent: operating cash flow was -$459.6M in FY2025 vs. -$108.7M in FY2024 (4.2x acceleration).
Balance sheet:
Runway:
Using the FY2025 annual operating cash outflow of -$459.6M against the $836M FY2025 year-end cash: roughly 1.8 years of runway from the annual-rate basis. However, the Q1 2026 press-release figure of -$314.7M in a single quarter, if sustained, implies a dramatically shorter runway of approximately 3-4 quarters from the $1.0–1.2B stated liquidity. The company has no path to self-funding; continued solvency depends on the ATM program remaining open and the stock price staying above levels that make new issuance economically feasible.
Share count and dilution:
---
At $13.95 and $4.54B market cap, NuScale trades at approximately 144x FY2025 revenue ($31.5M) and at a roughly $3.7B enterprise value (market cap minus $836M FY2025 year-end cash — a floor calculation that does not net liabilities). All earnings-based multiples are meaningless; operating losses are -$689.6M on $31.5M revenue.
For a pre-commercial option, the relevant comparison is: what commercialisation probability does the current price imply? Analyst targets range from $7 (Citi, May 2026) to $45 (Barclays) — a 6x spread that reflects narrative speculation rather than fundamental anchoring. BofA reinstated at Neutral / $12 (May 31, 2026), citing slow contract conversion and funding vulnerability. The mid-range Canaccord target of $25 implies roughly 79% upside from current price and requires at least one binding contract materialising.
Fair value range: $7–$22 (method: scenario-weighted). The lower bound ($7, in line with Citi) reflects no binding contract by end-2026, continued ATM dilution, and a market de-rating toward the pre-revenue cash-burn multiple; this implies roughly $3.5B market cap, or ~4x current annual liquidity. The upper bound ($22) reflects the RoPower FID signed plus a DOE loan conditional commitment in 2026, re-rating the stock toward a 10x P/S on a hypothetical $150–$200M forward licensing/engineering revenue run-rate. The Barclays $45 target requires the full TVA/ENTRA1 6 GW program materialising on schedule with no current contractual basis and is not supportable on a 12-month horizon. The current $13.95 price is toward the middle of this range, reflecting the market's ambiguous pricing of commercialisation probability in the absence of any confirmed contracts.
---
Institutional ownership data is not available in the fact sheet. Key ownership events from external sources (not XBRL-confirmed): Fluor Corporation sold approximately 111M shares for ~$2.43B between September 2025 and April 2026, fully exiting its position — this resolved a multi-year technical overhang. Management's active ATM program and the 662M authorized share ceiling signal that ongoing equity issuance is the operational survival plan, not a contingency. No insider buyback program has been disclosed in available data. No formal going-concern opinion or auditor material weakness is cited in available filings.
---
NuScale is the only U.S. company with full NRC SMR design approvals in a market where regulatory clearance is a multi-year, multi-hundred-million-dollar barrier. The demand curve for firm, 24/7, low-carbon power is structurally accelerating: IEA projects U.S. data center electricity demand to roughly double to ~35 GW by 2030, and hyperscalers have collectively announced 20+ GW of advanced nuclear financing plans. At $4.54B market cap and $836M year-end cash, the enterprise value is approximately $3.7B — pricing in significant but not absurd commercialisation probability for the only NRC-cleared SMR design.
Doosan reportedly has 12 VOYGR modules already in production, meaning if a first contract is signed, hardware lead-time is partially de-risked. The Fluor overhang is fully resolved, removing the single largest structural seller for the first time since the company went public — a catalyst pop will not be absorbed by a structural seller. If RoPower FID or the TVA/ENTRA1 PPA materialises, NuScale becomes the only company with an NRC-approved design, modules in production, and a signed commercial order — a combination no peer can match today. A single binding contract would likely re-rate the stock toward the $20–25 mid-range analyst target (45–79% upside from current price).
---
1. Revenue collapse (HIGH severity): FY2025 revenue $31.5M, down from $37.0M in FY2024. Q1 2026 revenue $0.6M (press-release-sourced; not XBRL-confirmed) — attributed to non-recurrence of one-time Romania license recognition. The underlying engineering/licensing revenue model is inherently lumpy and thin; true reactor revenue is a 2030+ event.
2. Cash burn explosion (HIGH severity): Operating cash flow deteriorated from -$108.7M (FY2024) to -$459.6M (FY2025) — a 4.2x acceleration in one year. Q1 2026 press-release figure of -$314.7M in a single quarter (not XBRL-confirmed) implies runway compression to approximately 3-4 quarters from stated $1.0–1.2B liquidity.
3. Dilution treadmill (HIGH severity): The February 2026 equity offering added ~75.9M shares at $13.18; the ongoing ATM program added further shares; authorized shares expanded to 662M. The company's survival plan is serial equity issuance, not a path to self-funding. If the stock corrects, the ATM program becomes economically punishing or unavailable, compressing runway further.
4. Zero binding contracts since 2023 UAMPS cancellation (HIGH severity): NuScale's only firm commercial order cancelled in 2023 after estimated plant costs rose from ~$5.3B to ~$9.3B for 462 MWe — a 75% cost overrun before groundbreaking. Nearly three years later, no binding commercial contracts exist. The TVA/ENTRA1 6 GW "collaborative agreement" is a planning framework; the Romania FID has already slipped its stated deadline.
5. Operating loss acceleration (HIGH severity): FY2025 operating loss -$689.6M vs. FY2024 -$138.7M — nearly 5x increase in one year. Revenue of $31.5M against a -$689.6M operating loss reflects deeply negative operating leverage that will persist for years.
6. Competitive moat erosion (MEDIUM-HIGH severity): Oklo received NRC design criteria approval May 2026; Kairos has 14 NRC topical reports approved and a signed Google/TVA PPA; X-energy filed an S-1 with $94.3M trailing revenue and DOE backing. Oklo's $11.6B market cap exceeds NuScale's $4.5B despite no full NRC design certification — the market is pricing competitor pipelines at a premium to NuScale's regulatory head-start.
7. UAMPS cost-escalation precedent (HIGH severity): The 2023 cancellation is empirical evidence that NuScale's 50 MWe modules could not be built at a cost that made the electricity economically competitive. The 77 MWe uprated design and VOYGR-12 configuration are the theoretical answer, but they are unbuilt. Until a plant is actually constructed and operated at cost, economic viability remains unproven — and the one real-world data point was sharply negative.
8. Retail promotion profile (MEDIUM severity): Near-daily coverage from StocksToTrade and TimothySykes (known retail momentum publishers) in May-June 2026; Motley Fool "mark your calendar" urgency headline (May 23, 2026); the stock ran ~40% in 6 weeks on no new binding commercial news. Analyst price targets span $7–$45 (6x range). The stock trades on narrative and is susceptible to sharp mean-reversion when catalysts disappoint. These signals match a promotion-adjacent profile but fall short of a confirmed coordinated paid-promotion campaign.
---
---
NuScale is a genuine first-mover on NRC regulatory approval and is positioned in a structural demand wave that is real. But regulatory moats only create value if converted into commercial revenue — and three years after its only firm contract cancelled, NuScale has not closed a single binding order. The financial trajectory is deteriorating: operating cash burn accelerated 4.2x in FY2025 and the Q1 2026 press-release figures suggest further acceleration. The company is on a dilution treadmill by design.
The honest framing: this is a high-variance binary position. If RoPower FID or TVA/ENTRA1 converts to a binding agreement in 2026, the stock re-rates sharply and the regulatory moat becomes commercially real for the first time. If neither converts — the base case given the pattern of slippage — the stock drifts toward Citi's $7 target as dilution compounds and competitors close the regulatory gap. The 40% run in six weeks on no new binding news (driven by DOE policy rhetoric and AI narrative) reflects the stock's susceptibility to both sharp rallies and sharp reversals on sentiment alone. At $13.95, the price is in the middle of a wide and honestly uncertain fair-value range.
Research, not investment advice. Figures sourced from SEC filings and public data; verify before acting.
Institutional ownership breakdown not available in fact sheet. Key event: Fluor Corporation fully exited its position (approximately 111M shares sold, Sept 2025–Apr 2026, ~$2.43B total per external sources) — resolves the largest overhang but also removes a long-term institutional anchor. Management ATM program and 662M authorized share ceiling indicate ongoing equity dilution as operational plan. No insider buyback program identified.
Research, rating, fair value & financials are as of the analysis on Jun 2, 2026. Generated by claude-sonnet-4-6 (pipeline). Not investment advice.